The latest Phase III trial study data shows Fuzeon, the new HIV drug from Trimeris, produces the same results of reducing HIV virus levels at 48 weeks as it did at 24 weeks, Trimeris and its partner Roche announced today.

Fuzeon recently was approved by the FDA on fast-track approval based in part on the 24-week trial results.

Some 30 percent of patients receiving Fuzeon in conjunction with other drugs showed “undetectable levels” of HIV so-called “load.”
However, Trimeris and Roche have both noted that the drug is not a cure for AIDS and does not prevent transmission of the disease from one person to another.

Fuzeon is administered twice daily through injection.